caresyntax Names Timothy Lantz as President

BOSTON, May 28, 2019 /PRNewswire/ — Caresyntax Corp., a pioneering provider of surgical automation, analytics and AI software and technologies, announced today the appointment of Timothy Lantz as the company’s President. In this role, Lantz will focus on product development and operations, critical functions as the company embarks upon key collaborations with major healthcare systems, improvement organizations and surgical robotics and device vendors in the US and abroad. Lantz brings over 15 years of leadership experience, most recently as Senior Vice President and General Manager at Sentry Data Systems, a US-based healthcare technology and analytics firm.

– Cross reference: Picture is available at AP Images (http://www.apimages.com) –

“Tim’s operating experience, market insights and US healthcare system expertise are unparalleled,” noted Dennis Kogan, Chairman and CEO of caresyntax. “He is a key addition to the team and will be instrumental as the company continues to build up  an open architecture ecosystem of digital applications improving quality and cost of surgery, jointly with its global development and distribution partners. I look forward to collaborating with Tim to accelerate caresyntax’s business growth and evolution.”

Kogan will continue to focus on long-term strategic initiatives, key customer relationships and expansion opportunities.

“I am thrilled to join the caresyntax team. This is an innovative, rapidly growing organization comprised of talented professionals from across the globe, dedicated to improving the quality of healthcare by providing enhanced interoperability, automation, and insights across the surgical continuum. I look forward to working with Dennis and the team to scale our presence here in the United States and establish caresyntax as a global leader in surgical innovation and analytics,” commented Timothy Lantz.   

About caresyntax
Caresyntax utilizes its proprietary, best-of-class workflow automation and data warehousing platforms to design software applications that support surgical vendors, healthcare improvement companies and providers in identifying and managing risk, automating workflows, enhancing knowledge sharing, and reducing surgical variability. Converging IoT technology and surgical analytics, the caresyntax platform is used in more than 6,300 operating rooms worldwide, transforming unstructured clinical and operational data into actionable, real-time insights. Clinical teams, as a result, enhance clinical performance, control surgical variation, and improve patient outcomes. The company was founded in 2013 and headquartered in Berlin, Germany. Its team of 115 people is located in Boston, Berlin, and other regional offices.

Media Contact:
Luke Walker, Director of Global Marketing Communications
caresyntax
E: luke.walker@caresyntax.com 
T: +49-1520-9386-794

 

View original content:http://www.prnewswire.com/news-releases/caresyntax-names-timothy-lantz-as-president-300857018.html

SOURCE caresyntax

Staff

Recent Posts

GE HealthCare Announces Cash Dividend for First Quarter of 2024

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…

2 hours ago

GE HealthCare to Feature Latest Technologies in Interventional Radiology Focused on Precision Care at SIR 2024

Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…

2 hours ago

Smartsheet Names Katie Rooney to Board of Directors

Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…

2 hours ago

The Centers for Medicare & Medicaid Services Revise National Coverage Determination for Stem Cell Transplantation

The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…

2 hours ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…

3 hours ago